Professor Paul Clarke leads the Director's Research Group.

Researcher biography

Paul Clarke is Director of The University of Queensland Diamantina Institute (UQDI), a leading translational medical research centre studying cancer, autoimmune diseases, infection and immunity, and the genetic basis of disease. Based at the $350 million Translational Research Institute at the Princess Alexandra Hospital site in Woolloongabba, scientists and clinical researchers at UQDI develop new methods for the prevention, detection and treatment of human diseases. Paul Clarke joined UQ in 2017 from the University of Dundee in Scotland where he was Professor of Cancer Cell Biology and Associate Dean (Research) in the School of Medicine. Previously, he was a Wellcome Trust Research Fellow at the European Molecular Biology Laboratory, Heidelberg and a Senior Research Fellow at the University of Manchester. Professor Clarke has served on national and international grant review panels and has worked in collaboration with industry, notably with Pfizer, AstraZeneca and Teva Pharmaceuticals. He has received a Medical Research Council Career Establishment Award, Royal Society-Wolfson Research Merit Award, and research fellowships from The Wellcome Trust and Cancer Research UK. He was elected a Fellow of the Royal Society of Biology in 2012. Professor Clarke's current research interests are the molecular mechanisms of cell division, chromosome instability and mitotic cell death. He also carries out research into the cellular responses to anti-cancer drugs.

Areas of research